MedTrace Logo

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

NCT01854567 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-06-26

No results posted yet for this study

Summary

The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.

Conditions

Interventions

BIOLOGICAL

Infusion of one MPC expanded cord unit and one unexpanded cord unit

Infusion of one MPC expanded cord unit and one unexpanded cord unit.

BIOLOGICAL

Infusion of two unexpanded cord blood units.

Umbilical Cord Blood.

Sponsors & Collaborators

  • Mesoblast, Ltd.

    lead INDUSTRY

Principal Investigators

  • Donna Skerrett, MD, MS · Mesoblast, Ltd.

  • Elizabeth J. Shpall, MD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-09-23
Completion
2017-05-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854567 on ClinicalTrials.gov